ArticleBrain & spine2025
Spondylodiscitis and infective endocarditis: A retrospective cohort analysis of clinical outcomes, microbiological profiles, and mortality in 312 patients.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coexistence of infective endocarditis (IE) and spondylodiscitis (SD) ranges between 7 % and 30 %, increasing particularly in patients older than 75 years. IE can occur without bacteremia, complicating early diagnosis and therapeutic strategies. Objectives: To determine the incidence and microbiological spectrum of IE among patients diagnosed and treated with SD, examine the prevalence of associated bacteremia, and evaluate associated clinical outcomes and mortality. Methods: We conducted a retrospective, monocentric study from January 2016 to December 2020 at a level one spinal surgery center. Included were adult patients (>18 years) with confirmed SD (positive MRI combined with histological and/or microbiological evidence) who underwent echocardiography. Variables analyzed were demographics, localization of SD, microbiological findings, comorbidities, therapeutic approaches, and mortality. Patients were divided into isolated SD and SD with concurrent IE (SD + IE). Results: Of 312 patients, 31 (9.9 %) had concurrent IE. Bacteremia was documented in 58 % overall but was absent in 16 % of IE cases. Patients with IE had a higher prevalence of coronary artery disease (45 % vs. 26 %; p = 0.0237). Enterococci were significantly more frequent in the IE group (35 % vs. 6 %; p = 0.021). Left heart involvement predominated (80 %), notably the aortic (38.7 %) and mitral valves (29 %). Spinal surgical interventions occurred less frequently in the IE group (45.2 % vs. 85.4 %). Mortality was significantly increased in IE patients (48.4 % vs. 11.74 %; p = 0.0157). Conclusions: Concomitant infective endocarditis (IE) significantly increases mortality in patients with spondylodiscitis (SD), even in the absence of bacteremia. Routine echocardiographic screening (TTE/TEE) must be standard, as its omission risks missed diagnoses. Interdisciplinary collaboration is essential for timely diagnosis, coordinated treatment, and improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.